Biotech Values

[DewDiligence]

>…if approved, even if sanofi launches a generic, one big offset is you'd think it lowers the perceived approval risk for something like Copaxone.<

I wonder if Teva would launch an AG for Copaxone. If they did, it would put the company’s Washington-based lobbyists in an awkward position :- )